Mauro Ferrari


Mauro Ferrari is a nanoscientist and leader in the field of nanomedicine. He served as special expert on nanotechnology for the National Cancer Institute and was instrumental in establishing the Alliance for Nanotechnology in Cancer in 2004.
On 1 January 2020, Ferrari was made president of the European Research Council. On 7 April 2020, Ferrari resigned from his role as president of the ERC, stating to the media that he was "extremely disappointed by the European response” to the pandemic and expressing frustration over opposition to his efforts to launch a scientific program to combat the virus. On 8 April 2020, an EU Commission spokesperson confirmed the resignation, but did not elaborate. Subsequently, the ERC disputed details surrounding Ferrari's resignation.

Early life and education

Ferrari was born in Padova, Italy in 1959. He spent his early years in Udine and Florence before attending the University of Padova and earning his Laurea in Mathematics in 1985. He moved to Berkeley, California where he earned his master's and doctorate in mechanical engineering from the University of California Berkeley.

Career

Professor of Engineering

Ferrari became an associate professor of engineering at Berkeley, then moved to the Ohio State University as professor of bioengineering, internal medicine, and mechanical engineering.
He studied medicine at the Ohio State University concurrent with his faculty appointment from 2002-2004.

Cancer research

He moved to the MD Anderson Cancer Center and University of Texas Health Science Center at Houston, TX to become the chair of the department of nanomedicine and biomedical engineering, and then in 2010 accepted the position of president and CEO of the Houston Methodist Research Institute in Houston, TX.
Ferrari was appointed as Chief Commercialization Officer of Houston Methodist in 2018, and retired in 2019.

ERC President (2020)

In 2019, the European Commission appointed Ferrari as the next President of the European Research Council, succeeding Jean-Pierre Bourguignon; he was selected by a search committee chaired by Mario Monti. He took the post on 1 January 2020.
Ferrari resigned in 7 April 2020, citing his disappointment at the lack of coordinated EU action to address the COVID-19 pandemic. Ferrari was not alone in his criticism of the EU response to COVID-19.The ERC countered that calling for specific research was contrary to their mandate. According to Science Magazine, "ERC, set up to reward bottom-up basic research ideas, does not designate money for specific research areas....Other EU organs can and do pay for research in particular fields, including COVID-19, but ERC is designed to protect science from politics. Ferrari writes that 'the expected burden of death, suffering, societal transformation, and economic devastation' of the pandemic justifies breaking this rule."
The ERC responded on 8 April 2020: "...we regret Professor Ferrari's statement, which at best is economical with the truth." The ERC stated that Ferrari's "resignation in fact followed a written unanimous vote of no confidence”. They cited "a complete lack of appreciation for the raison-d’être of the ERC", "a lack of engagement with the ERC", with Ferrari "failing to participate in many important meetings, spending extensive time in the USA and failing to defend the ERC’s programme and mission," making "several personal initiatives within the Commission" without consulting the ERC, and being "involved in multiple external enterprises, some academic and some commercial, which took a lot of his time and effort and appeared on several occasions to take precedence over his commitment to ERC." Ferrari disputed the ERC claims of his failing to meet his obligations and their accusations of inappropriate outside involvements.

Other activities

Corporate boards

Ferrari's research uses nanotechnology, microtechnology, physical sciences, mathematics, biomechanics, and material sciences to develop new technologies for health care applications like drug delivery and cancer therapeutics. He leads a physical sciences in oncology center, one of a network of centers sponsored by the National Institutes of Health National Cancer Center. The research of this center focuses on understanding the physical and biomechanical biological barriers that reduce the efficacy of cancer therapeutics. He developed a new drug called iNPG-pDox, composed of silicon nanoparticles loaded with polymeric doxorubicin, that had better results at lower doses in animal models compared to standard doxorubicin chemotherapy for metastatic breast cancer.

Published works

Ferrari has produced more than 350 publications, including seven books and 41 issued patents in the US and Europe.

Books

Patents

Ferrari met and married his first wife Marialuisa while they were both students at the University of Padova, and they moved to Berkeley, California. While he was faculty at the University of California Berkeley, Marialuisa died from cancer.
Ferrari married Paola Del Zotto from Udine, Italy in 1995. He has five children, including two sets of twins.